陈 瑜:药品不良反应相关知识科普之窗

2018-04-16 陈 瑜 醉药山人

为什么要警惕药品不良反应有些药品不良反应是难以预测的。而且新药上市前临床试验的样本量有限 (500~3000),病种单一,多数情况下排除特殊人群(老人、孕妇和儿童),因此一些罕见的不良反应、迟发性反应、发生于特殊人群的不良反应难于发现。有些问题必须在大面积人群使用后方能发现。因此,应警惕药品的不良反应,尤其应警惕新上市药品的不良反应。怎样预防药品不良反应药品不良反应的预防是一个关系全社会的系统

为什么要警惕药品不良反应

有些药品不良反应是难以预测的。而且新药上市前临床试验的样本量有限 (500~3000),病种单一,多数情况下排除特殊人群(老人、孕妇和儿童),因此一些罕见的不良反应、迟发性反应、发生于特殊人群的不良反应难于发现。有些问题必须在大面积人群使用后方能发现。因此,应警惕药品的不良反应,尤其应警惕新上市药品的不良反应。

怎样预防药品不良反应

药品不良反应的预防是一个关系全社会的系统工程。目前我国已经建立了从国家到地方的专门药品不良反应监测机构,出台了《药品不良反应报告和监测管理办法》,从政府层面,该项工作已经开展20多年,并将继续强化,国家食品药品监督管理总局会定时根据数据库中监测到的药品不良反应数据发布药品不良反应相关信息,您可根据自身需求登录国家食药局网站做相关查询;其次,药品生产经营企业和医疗预防保健机构应该设立相应的部门,认真地收集、报告药品不良反应病例;然后,广播电台、电视、报刊、杂志应该经常宣传普及合理用药、安全用药的教育,消费者也应该努力学习一些合理用药、安全用药的知识,提高这方面的自我保护能力,同时消费者应在用药前仔细研读药品说明书,严格遵守说明书的规定使用药物,安全用药。

应该怎样治疗药品不良反应

药品不良反应的治疗原则和其他常见病、多发病一致,只要使用了药物,身体出现不适,就应该考虑是否与药物有关,并尽快找到专业的医务人员,将自身疾病及用药的情况告知医生,并将自己的顾虑一并告知医生,再由医务人员进行进一步判断及处理,一般情况下,如果服药过程中出现不良反应,及时停药确实能改善症状,但有些特殊药物不能随意停药,随意停药可导致撤药反应,如正使用大剂量激素治疗的患者,如突然停药可导致严重的撤药综合征,故在做出停药的决定前,最好经过医生的判断。医生在判断后可能会给予相应的处理,如停药或规律减量直至停药,使用抵抗不良反应的其他药物,或有助于药物排出体外的药物等。

药品不良事件(Adverse Drug Events,ADE)和药品不良反应(Adverse Drug Reaction,ADR)含义区别

一般来说,药品不良反应是指因果关系已确定的反应,而药品不良事件是指因果关系尚未确定的反应。它在国外的药品说明书中经常出现,此反应不能肯定是由该药引起的,尚需要进一步评估。国际上给药品不良事件下的定义为:药品不良事件是指药物治疗过程中出现的不良临床事件,它不一定与该药有明确的因果关系。

什么是药品不良反应监测

药品不良反应监测主要是监测上市后药品的不良反应情况,,是药品再评价工作的一部分。监测工作的主要内容是:

(1) 收集药品不良反应信息,对药品不良反应的危害情况进行进一步的调查,及时向药品监督管理部门报告,提出对有关药品如何加强管理的意见、建议;(2)及时向药品生产、经营企业、医疗预防保健机构和社会大众反馈药品不良反应信息,防止药品不良反应的重复发生,保护人民的用药安全。

关于中药的不良反应是不是比化学药品少的问题

中药的使用讲究辨证施治、合理组方、因人而异、随证加减,多数中药都经过炮制,有助于减少和避免不良反应。是药三分毒,不管是口服的中成药或者静脉使用的中成药、汤剂等,外用的中药膏等,都有不良反应的发生。这些反应可能与不遵守辨证施治的原则或者辨证不当,组方不合理,中药材质量有问题有关,也可能是药物自身的药理作用导致。故在使用中药的过程中一样要注意药品不良反应的防治。

加强药品不良反应报告和监测有哪些激励与约束机制

药品不良反应报告和监测是一项复杂的社会性工作,事关全社会合理用药水平, 是各级政府必须办好的一项社会事业。鉴于当前药品不良反应报告和监测工作中存在的问题,进一步加强药品不良反应报告和监测工作应当从建立和完善相应的激励与约束机制入手。

(1)建立和完善药品生产再评价激励机制。国家在确定药品上市价格时,将药品上市后再评价成本作为其中因素之一,鼓励和要求药品生产企业建立药品上市后再评价体系。设立监测机构,聘任监测人员,健全监测制度,对上市后的药品进行跟踪随访,按期制定上报上市药品再评价报告,及时发现、报告上市药品新的不良反应,经认定确切的及时纳入相应的药品说明书。

(2)建立和完善药品流通不良反应监测工作的激励机制。国家在核定药品流通价格时,根据药品的注册和上市时间长短,应考虑药品不良反应监测的成本需要, 要求药品经营企业建立药品不良反应报告和监测体系,每年度按规定报告药品不良反应事件。

(3)建立和完善医疗机构药品不良反应报告和监测激励机制。

由于非营利性医疗机构占多数,各级政府可以设立适当的医疗机构药品不良反应监测基金,作为医疗机构开展药品不良反应工作的补偿,也可以规定医疗机构从药品销售纯收入中提取一定的药品不良反应监测工作经费。要求医疗机构按规定报告药品不良反应病例。

(4)建立群众报告药品不良反应激励机制。可以按地区为单元,制定并向社会公开药品不良反应报告方式和渠道,设立不良反应报告酬金,收到有价值药品不良反应报告即向报告者兑现一定酬金。

(5)建立药品不良反应赔偿机制。对应当发现而未发现或应当避免而未避免发生严重药品不良反应而造成人身伤害的,相关的药品生产、经营企业或医疗机构均应承担一定的赔偿责任。通过完善和实施这些激励和约束机制,提高药品生产、经营企业、医疗机构开展药品不良反应监测工作的积极性,规范药品不良反应监测与报告工作机制,提高整个药品不良反应监测与报告水平,促进合理用药向纵深发展,为人民群众健康服务。

作者 | 陈 瑜 广东省药学会 深圳市宝安区妇幼保健院

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1840556, encodeId=70fb1840556ad, content=<a href='/topic/show?id=9401204912f' target=_blank style='color:#2F92EE;'>#不良反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20491, encryptionId=9401204912f, topicName=不良反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Wed Jul 11 07:48:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045674, encodeId=3fe020456e4a2, content=<a href='/topic/show?id=57198e34821' target=_blank style='color:#2F92EE;'>#药品不良反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87348, encryptionId=57198e34821, topicName=药品不良反应)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iaP1mV9qBwx5tE2F4xcG1r4x1PibWvluIFLB8VsViakqNMBia2Z0wFibVrYwDEILvHB1OomzzTAAGy5MVl5BrdEv9Bw/132, createdBy=e11f100, createdName=guguangxiang, createdTime=Tue Jun 19 11:48:00 CST 2018, time=2018-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307415, encodeId=d1a830e41504, content=学了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Fri Apr 20 04:54:06 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307270, encodeId=b14f30e27080, content=学了, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Thu Apr 19 12:29:10 CST 2018, time=2018-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306563, encodeId=026c306563f5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI06MUzr7AI0nTlsgpDTRvVB51yAMdGfTKe8roX48ibEeqHD1dz3UibUa9SibU24UPLcEozJiaSB67WvQ/132, createdBy=fca0106828, createdName=Ramsey, createdTime=Tue Apr 17 06:54:21 CST 2018, time=2018-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306335, encodeId=851530633554, content=一起学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/TDiaAWyicHgedzX3wKo3qcxudVJib7AfibfvNeufHRF2jG3Bw8MmZyWjIhtBV1mpJI7Sy9n7RcBKK5t3CuOKuOFxkg/0, createdBy=dd702206933, createdName=wzb521zf, createdTime=Mon Apr 16 12:55:35 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306328, encodeId=47633063285e, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Mon Apr 16 12:43:59 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306325, encodeId=66da3063254b, content=应该, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Mon Apr 16 12:43:22 CST 2018, time=2018-04-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1840556, encodeId=70fb1840556ad, content=<a href='/topic/show?id=9401204912f' target=_blank style='color:#2F92EE;'>#不良反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20491, encryptionId=9401204912f, topicName=不良反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Wed Jul 11 07:48:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045674, encodeId=3fe020456e4a2, content=<a href='/topic/show?id=57198e34821' target=_blank style='color:#2F92EE;'>#药品不良反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87348, encryptionId=57198e34821, topicName=药品不良反应)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iaP1mV9qBwx5tE2F4xcG1r4x1PibWvluIFLB8VsViakqNMBia2Z0wFibVrYwDEILvHB1OomzzTAAGy5MVl5BrdEv9Bw/132, createdBy=e11f100, createdName=guguangxiang, createdTime=Tue Jun 19 11:48:00 CST 2018, time=2018-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307415, encodeId=d1a830e41504, content=学了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Fri Apr 20 04:54:06 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307270, encodeId=b14f30e27080, content=学了, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Thu Apr 19 12:29:10 CST 2018, time=2018-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306563, encodeId=026c306563f5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI06MUzr7AI0nTlsgpDTRvVB51yAMdGfTKe8roX48ibEeqHD1dz3UibUa9SibU24UPLcEozJiaSB67WvQ/132, createdBy=fca0106828, createdName=Ramsey, createdTime=Tue Apr 17 06:54:21 CST 2018, time=2018-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306335, encodeId=851530633554, content=一起学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/TDiaAWyicHgedzX3wKo3qcxudVJib7AfibfvNeufHRF2jG3Bw8MmZyWjIhtBV1mpJI7Sy9n7RcBKK5t3CuOKuOFxkg/0, createdBy=dd702206933, createdName=wzb521zf, createdTime=Mon Apr 16 12:55:35 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306328, encodeId=47633063285e, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Mon Apr 16 12:43:59 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306325, encodeId=66da3063254b, content=应该, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Mon Apr 16 12:43:22 CST 2018, time=2018-04-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1840556, encodeId=70fb1840556ad, content=<a href='/topic/show?id=9401204912f' target=_blank style='color:#2F92EE;'>#不良反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20491, encryptionId=9401204912f, topicName=不良反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Wed Jul 11 07:48:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045674, encodeId=3fe020456e4a2, content=<a href='/topic/show?id=57198e34821' target=_blank style='color:#2F92EE;'>#药品不良反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87348, encryptionId=57198e34821, topicName=药品不良反应)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iaP1mV9qBwx5tE2F4xcG1r4x1PibWvluIFLB8VsViakqNMBia2Z0wFibVrYwDEILvHB1OomzzTAAGy5MVl5BrdEv9Bw/132, createdBy=e11f100, createdName=guguangxiang, createdTime=Tue Jun 19 11:48:00 CST 2018, time=2018-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307415, encodeId=d1a830e41504, content=学了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Fri Apr 20 04:54:06 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307270, encodeId=b14f30e27080, content=学了, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Thu Apr 19 12:29:10 CST 2018, time=2018-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306563, encodeId=026c306563f5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI06MUzr7AI0nTlsgpDTRvVB51yAMdGfTKe8roX48ibEeqHD1dz3UibUa9SibU24UPLcEozJiaSB67WvQ/132, createdBy=fca0106828, createdName=Ramsey, createdTime=Tue Apr 17 06:54:21 CST 2018, time=2018-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306335, encodeId=851530633554, content=一起学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/TDiaAWyicHgedzX3wKo3qcxudVJib7AfibfvNeufHRF2jG3Bw8MmZyWjIhtBV1mpJI7Sy9n7RcBKK5t3CuOKuOFxkg/0, createdBy=dd702206933, createdName=wzb521zf, createdTime=Mon Apr 16 12:55:35 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306328, encodeId=47633063285e, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Mon Apr 16 12:43:59 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306325, encodeId=66da3063254b, content=应该, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Mon Apr 16 12:43:22 CST 2018, time=2018-04-16, status=1, ipAttribution=)]
    2018-04-20 哈哈869

    学了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1840556, encodeId=70fb1840556ad, content=<a href='/topic/show?id=9401204912f' target=_blank style='color:#2F92EE;'>#不良反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20491, encryptionId=9401204912f, topicName=不良反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Wed Jul 11 07:48:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045674, encodeId=3fe020456e4a2, content=<a href='/topic/show?id=57198e34821' target=_blank style='color:#2F92EE;'>#药品不良反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87348, encryptionId=57198e34821, topicName=药品不良反应)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iaP1mV9qBwx5tE2F4xcG1r4x1PibWvluIFLB8VsViakqNMBia2Z0wFibVrYwDEILvHB1OomzzTAAGy5MVl5BrdEv9Bw/132, createdBy=e11f100, createdName=guguangxiang, createdTime=Tue Jun 19 11:48:00 CST 2018, time=2018-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307415, encodeId=d1a830e41504, content=学了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Fri Apr 20 04:54:06 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307270, encodeId=b14f30e27080, content=学了, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Thu Apr 19 12:29:10 CST 2018, time=2018-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306563, encodeId=026c306563f5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI06MUzr7AI0nTlsgpDTRvVB51yAMdGfTKe8roX48ibEeqHD1dz3UibUa9SibU24UPLcEozJiaSB67WvQ/132, createdBy=fca0106828, createdName=Ramsey, createdTime=Tue Apr 17 06:54:21 CST 2018, time=2018-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306335, encodeId=851530633554, content=一起学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/TDiaAWyicHgedzX3wKo3qcxudVJib7AfibfvNeufHRF2jG3Bw8MmZyWjIhtBV1mpJI7Sy9n7RcBKK5t3CuOKuOFxkg/0, createdBy=dd702206933, createdName=wzb521zf, createdTime=Mon Apr 16 12:55:35 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306328, encodeId=47633063285e, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Mon Apr 16 12:43:59 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306325, encodeId=66da3063254b, content=应该, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Mon Apr 16 12:43:22 CST 2018, time=2018-04-16, status=1, ipAttribution=)]
    2018-04-19 哈哈869

    学了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1840556, encodeId=70fb1840556ad, content=<a href='/topic/show?id=9401204912f' target=_blank style='color:#2F92EE;'>#不良反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20491, encryptionId=9401204912f, topicName=不良反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Wed Jul 11 07:48:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045674, encodeId=3fe020456e4a2, content=<a href='/topic/show?id=57198e34821' target=_blank style='color:#2F92EE;'>#药品不良反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87348, encryptionId=57198e34821, topicName=药品不良反应)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iaP1mV9qBwx5tE2F4xcG1r4x1PibWvluIFLB8VsViakqNMBia2Z0wFibVrYwDEILvHB1OomzzTAAGy5MVl5BrdEv9Bw/132, createdBy=e11f100, createdName=guguangxiang, createdTime=Tue Jun 19 11:48:00 CST 2018, time=2018-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307415, encodeId=d1a830e41504, content=学了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Fri Apr 20 04:54:06 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307270, encodeId=b14f30e27080, content=学了, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Thu Apr 19 12:29:10 CST 2018, time=2018-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306563, encodeId=026c306563f5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI06MUzr7AI0nTlsgpDTRvVB51yAMdGfTKe8roX48ibEeqHD1dz3UibUa9SibU24UPLcEozJiaSB67WvQ/132, createdBy=fca0106828, createdName=Ramsey, createdTime=Tue Apr 17 06:54:21 CST 2018, time=2018-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306335, encodeId=851530633554, content=一起学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/TDiaAWyicHgedzX3wKo3qcxudVJib7AfibfvNeufHRF2jG3Bw8MmZyWjIhtBV1mpJI7Sy9n7RcBKK5t3CuOKuOFxkg/0, createdBy=dd702206933, createdName=wzb521zf, createdTime=Mon Apr 16 12:55:35 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306328, encodeId=47633063285e, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Mon Apr 16 12:43:59 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306325, encodeId=66da3063254b, content=应该, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Mon Apr 16 12:43:22 CST 2018, time=2018-04-16, status=1, ipAttribution=)]
    2018-04-17 Ramsey

    学习了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1840556, encodeId=70fb1840556ad, content=<a href='/topic/show?id=9401204912f' target=_blank style='color:#2F92EE;'>#不良反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20491, encryptionId=9401204912f, topicName=不良反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Wed Jul 11 07:48:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045674, encodeId=3fe020456e4a2, content=<a href='/topic/show?id=57198e34821' target=_blank style='color:#2F92EE;'>#药品不良反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87348, encryptionId=57198e34821, topicName=药品不良反应)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iaP1mV9qBwx5tE2F4xcG1r4x1PibWvluIFLB8VsViakqNMBia2Z0wFibVrYwDEILvHB1OomzzTAAGy5MVl5BrdEv9Bw/132, createdBy=e11f100, createdName=guguangxiang, createdTime=Tue Jun 19 11:48:00 CST 2018, time=2018-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307415, encodeId=d1a830e41504, content=学了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Fri Apr 20 04:54:06 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307270, encodeId=b14f30e27080, content=学了, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Thu Apr 19 12:29:10 CST 2018, time=2018-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306563, encodeId=026c306563f5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI06MUzr7AI0nTlsgpDTRvVB51yAMdGfTKe8roX48ibEeqHD1dz3UibUa9SibU24UPLcEozJiaSB67WvQ/132, createdBy=fca0106828, createdName=Ramsey, createdTime=Tue Apr 17 06:54:21 CST 2018, time=2018-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306335, encodeId=851530633554, content=一起学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/TDiaAWyicHgedzX3wKo3qcxudVJib7AfibfvNeufHRF2jG3Bw8MmZyWjIhtBV1mpJI7Sy9n7RcBKK5t3CuOKuOFxkg/0, createdBy=dd702206933, createdName=wzb521zf, createdTime=Mon Apr 16 12:55:35 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306328, encodeId=47633063285e, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Mon Apr 16 12:43:59 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306325, encodeId=66da3063254b, content=应该, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Mon Apr 16 12:43:22 CST 2018, time=2018-04-16, status=1, ipAttribution=)]
    2018-04-16 wzb521zf

    一起学习学习

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1840556, encodeId=70fb1840556ad, content=<a href='/topic/show?id=9401204912f' target=_blank style='color:#2F92EE;'>#不良反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20491, encryptionId=9401204912f, topicName=不良反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Wed Jul 11 07:48:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045674, encodeId=3fe020456e4a2, content=<a href='/topic/show?id=57198e34821' target=_blank style='color:#2F92EE;'>#药品不良反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87348, encryptionId=57198e34821, topicName=药品不良反应)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iaP1mV9qBwx5tE2F4xcG1r4x1PibWvluIFLB8VsViakqNMBia2Z0wFibVrYwDEILvHB1OomzzTAAGy5MVl5BrdEv9Bw/132, createdBy=e11f100, createdName=guguangxiang, createdTime=Tue Jun 19 11:48:00 CST 2018, time=2018-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307415, encodeId=d1a830e41504, content=学了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Fri Apr 20 04:54:06 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307270, encodeId=b14f30e27080, content=学了, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Thu Apr 19 12:29:10 CST 2018, time=2018-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306563, encodeId=026c306563f5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI06MUzr7AI0nTlsgpDTRvVB51yAMdGfTKe8roX48ibEeqHD1dz3UibUa9SibU24UPLcEozJiaSB67WvQ/132, createdBy=fca0106828, createdName=Ramsey, createdTime=Tue Apr 17 06:54:21 CST 2018, time=2018-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306335, encodeId=851530633554, content=一起学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/TDiaAWyicHgedzX3wKo3qcxudVJib7AfibfvNeufHRF2jG3Bw8MmZyWjIhtBV1mpJI7Sy9n7RcBKK5t3CuOKuOFxkg/0, createdBy=dd702206933, createdName=wzb521zf, createdTime=Mon Apr 16 12:55:35 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306328, encodeId=47633063285e, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Mon Apr 16 12:43:59 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306325, encodeId=66da3063254b, content=应该, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Mon Apr 16 12:43:22 CST 2018, time=2018-04-16, status=1, ipAttribution=)]
    2018-04-16 神功盖世

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1840556, encodeId=70fb1840556ad, content=<a href='/topic/show?id=9401204912f' target=_blank style='color:#2F92EE;'>#不良反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20491, encryptionId=9401204912f, topicName=不良反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Wed Jul 11 07:48:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045674, encodeId=3fe020456e4a2, content=<a href='/topic/show?id=57198e34821' target=_blank style='color:#2F92EE;'>#药品不良反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87348, encryptionId=57198e34821, topicName=药品不良反应)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iaP1mV9qBwx5tE2F4xcG1r4x1PibWvluIFLB8VsViakqNMBia2Z0wFibVrYwDEILvHB1OomzzTAAGy5MVl5BrdEv9Bw/132, createdBy=e11f100, createdName=guguangxiang, createdTime=Tue Jun 19 11:48:00 CST 2018, time=2018-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307415, encodeId=d1a830e41504, content=学了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Fri Apr 20 04:54:06 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307270, encodeId=b14f30e27080, content=学了, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Thu Apr 19 12:29:10 CST 2018, time=2018-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306563, encodeId=026c306563f5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI06MUzr7AI0nTlsgpDTRvVB51yAMdGfTKe8roX48ibEeqHD1dz3UibUa9SibU24UPLcEozJiaSB67WvQ/132, createdBy=fca0106828, createdName=Ramsey, createdTime=Tue Apr 17 06:54:21 CST 2018, time=2018-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306335, encodeId=851530633554, content=一起学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/TDiaAWyicHgedzX3wKo3qcxudVJib7AfibfvNeufHRF2jG3Bw8MmZyWjIhtBV1mpJI7Sy9n7RcBKK5t3CuOKuOFxkg/0, createdBy=dd702206933, createdName=wzb521zf, createdTime=Mon Apr 16 12:55:35 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306328, encodeId=47633063285e, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Mon Apr 16 12:43:59 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306325, encodeId=66da3063254b, content=应该, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Mon Apr 16 12:43:22 CST 2018, time=2018-04-16, status=1, ipAttribution=)]
    2018-04-16 医者仁心5538

    应该

    0

相关资讯

30个药被重点监控!

近日,业内流传出一份河南省《关于执行用量大目录药品联动价格的通知》,要求4月2日起执行用量大药品联动价格。

药品二次议价,要被整治了

借“二次议价”牟利,这是很多医院的常规操作手段。招标机构也经常眼一只眼、闭一只眼。企业却对之深恶痛绝,却毫无办法。

广东省药品企业管理出新规 明天就试行了!

近日,广东省品食品药监局对现行的药品零售(连锁)企业管理规定进行了修订,新修订的药品零售(连锁)企业管理规定将于本月15日起试行,推进药品的分类分级管理和提高药剂人员的配备标准为此次修订条例的两大看点。推进药品零售企业实施分级分类的动态管理据了解,新规定将根据药品零售经营规模的适应程度等实际情况将药品零售企业从小到大划分,具体以一类、二类和三类为标准来核定药品零售企业的经营范围。同时将以A级、B

中国药品审评审批制度改革提速,药品申请积压现象缓解

日前,原国家食品药品监管总局(现国家市场监管总局)发布了《2017年度药品审评报告》(以下简称《报告》)。报告显示,在鼓励药物创新、提高药品质量方面,我国药品审评审批制度改革发挥了重要作用。2015年,国务院发布《关于改革药品医疗器械审评审批制度的意见》,提出了12项改革任务;2017年,中办、国办发布《关于深化审评审批制度改革鼓励药品医疗器械创新的意见》,提出鼓励药品创新36条意见。“这三年

6省发文,优先使用这些药品

4月11日,黑龙江卫计委发布《关于进一步改革完善药品生产流通使用政策具体意见的通知》(下称《通知》)。

总局公布,70药品要上市,都是亿级爆品!

3月22日,总局发布《2017年度药品审评报告》(下称报告)。这份对2017年药品审评总结的报告中,透露利好信息:有50个药品通过优先审评程序,得以加快、优先批准上市。